

Award Number: W81XWH-11-1-0220

TITLE: Synthetic Lethality as a Targeted Approach to Advanced Prostate Cancer

PRINCIPAL INVESTIGATOR: Douglas V. Faller, Ph.D., M.D.

CONTRACTING ORGANIZATION: Boston University Medical Campus
Boston, MA 02118

REPORT DATE: March 2012

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE March 2012		2. REPORT TYPE Annual		3. DATES COVERED 1 March 2011 - 29 February 2012	
4. TITLE AND SUBTITLE Synthetic Lethality as a Targeted Approach to Advanced Prostate Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-11-1-0220	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Douglas V. Faller, Ph.D., M.D. E-Mail: dbarnett@elintrix.com				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Boston University Boston, MA 02118				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Prostate carcinogenesis is closely linked to aberrant activation of Ras or Ras signaling pathways (<i>e.g.</i> , Raf-MEK, or PI ₃ K pathways). The incidence of activating PI ₃ K mutations in early and advanced prostate cancer, or loss of PTEN is very high. Increased expression of the Ras/Raf/MEK/ERK pathway has been associated with advanced prostate cancer, hormonal independence and a poor prognosis. We have demonstrated that, when aberrantly activated, Ras is lethal to the cell unless a survival pathway also initiated by Ras is active. This survival pathway <u>requires</u> PKC- δ . Unlike the classical PKC isozymes, PKC- δ is not required for cell survival, and its inhibition or down-regulation in normal cells and tissues has no significant adverse effects. Inhibition of PKC- δ in human and murine cells containing an activated Ras protein, however, initiates rapid and profound apoptosis. In this work, we are testing the <i>hypothesis</i> that inhibition or down-regulation of PKC- δ in human and murine models of prostate cancer with aberrant activation of Ras signaling will cause targeted cytotoxicity in these tumors.					
15. SUBJECT TERMS Prostate cancer; Ras; small molecule inhibitors; drug development					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)
			UU	32	

Table of Contents

	<u>Page</u>
Introduction.....	3
Body.....	4
Key Research Accomplishments.....	30
Reportable Outcomes.....	30
Conclusion.....	30
References.....	31
Appendices.....	31

INTRODUCTION:

Although activating point mutations of Ras in prostate cancer, are not common, prostate carcinogenesis, in particular, is closely linked to aberrant activation of Ras or Ras signaling pathways (*e.g.*, Raf-MEK, or PI₃K pathways). The incidence of activating PI₃K mutations in early and advanced prostate cancer, or loss of PTEN is very high. Increased expression of the Ras/Raf/MEK/ERK pathway has been associated with advanced prostate cancer, hormonal independence and a poor prognosis. Strategies have been devised to target various stages of Ras signaling, ranging from inhibiting protein expression *via* antisense oligonucleotides, to blocking post-translational modification with farnesyltransferase inhibitors, to inhibiting downstream effectors. Unfortunately, these have shown minimal if any activity in prostate carcinoma in clinical trials, or have been limited by toxicity. Because wild-type Ras and its downstream effectors are required for many critical cellular functions in normal cells, the therapeutic window for inhibiting Ras directly may be too narrow to exploit. Our novel alternative strategy would circumvent this limitation. We have demonstrated that, when aberrantly activated, Ras is lethal to the cell unless a survival pathway also initiated by Ras is active. This survival pathway requires PKC δ .¹ Unlike the classical PKC isozymes, PKC δ is not required for cell survival, and its inhibition or down-regulation in normal cells and tissues has no significant adverse effects. Inhibition of PKC δ in human and murine cells containing an activated Ras protein, however, initiates rapid and profound apoptosis. This molecular approach, targeting tumor cells containing a mutated oncogenic protein (and sparing normal cells), by altering a second protein or its activity, is sometimes termed “synthetic lethality.”^{2,3} Analogously, the dependency of tumor cells upon the activity of a non-oncogenic protein is sometimes termed “non-oncogene addiction.”

Hypothesis: inhibition or down-regulation of PKC δ in human and murine models of prostate cancer with aberrant activation of Ras signaling will cause targeted cytotoxicity in these tumors. The Specific Aims of this Idea Proposal are: i.) Test the hypothesis that inhibition or down-regulation of PKC δ in human prostate cancer cell lines with dysregulation of Ras pathways selectively induces apoptosis. Using molecular modeling, multiple analogs of the current lead PKC δ inhibitor have been predicted to have more specificity and higher potency than the current lead compound. A collaboration with a leading medicinal chemist produced one analog with superior pharmacokinetics. Thirty six next generation other analogs have been synthesized and tested for activity and isozyme specificity *in vitro* and in tissue culture. The best one or two analogs will then be tested *in vivo* (below) in a head-to-head comparison with the current lead compound to identify an optimal PKC δ inhibitor. ii.) Determine whether constitutive activation of *selected Ras effector pathways alone* (PI₃K Pathway, *via* the commonly-occurring loss of PTEN or activating mutations in PIK3CA [p110 α]; or constitutive, aberrant activation of the MEK-ERK signaling pathway) is sufficient to make prostate cancer cells susceptible to apoptosis after PKC- δ inhibition. iii.) Test the ability of PKC- δ inhibitors to induce selective cytotoxicity in human *prostate cancer stem cells*. iv.) Test this targeted approach in *in vivo* models of human prostate carcinoma. A xenograft model will be employed, utilizing an activating Ras-mutant human prostate carcinoma cell line and a human prostate carcinoma cell line with aberrantly-activated Raf-signaling.

Innovation: Ras signaling is an attractive target for therapy of prostate cancer, but approaches aimed at Ras itself, or its critical signaling pathways, which are required in normal tissues, have had limited success. This “non-oncogene addiction” approach, however, exploits a weakness of

tumor cells with aberrant activation of Ras or Ras effectors – their absolute requirement for a survival pathway mediated by PKC- δ . In contrast, normal cells and tissues do not require PKC- δ .

Impact: Current therapies for prostate cancer are inadequate, and aberrant activation of Ras or Ras pathways are common. A novel therapeutic modality selectively targeting prostate cancers with activation of Ras or Ras pathways would make a significant impact on the way prostate cancer is treated.




Fig. 1: Human prostate cancer cells were infected with lentiviral vector containing a non-specific shRNA (NS-V) or a PKC δ -specific shRNA (siPKC δ -V), and an LDH release cytotoxicity assay was carried out at 24 hrs. “+” represents the maximum total release of LDH from cells artificially lysed, according to manufacturer’s instructions. Background release was subtracted from the values. Error bars indicate SEM.

BODY:

TASK 1: Testing human prostate cancer cell lines for sensitivity to PKC δ inhibition

Status: IN PROGRESS

Methods: Using cancer cell lines with known activating mutations in H-Ras, comparing these with human prostate cells containing wild-type Ras alleles: (non-Ras-mutated) prostate epithelial cells

Task 1a) Using siRNA to suppress PKC δ

Task 1b) Using new, specific small-molecule PKC δ inhibitors.

- Verify their PKC δ inhibitory activity and isozyme-specificity will be verified *in vitro* using purified PKC isozymes
- Testing their ability to induce apoptosis in prostate cancer cell lines, and selection of the most potent and PKC δ isozyme-selective for *in vivo* testing.

Assays: MTS assay for enumeration of cells at 48 and 72 hrs after treatment. LDH release assays or flow cytometry assays to assess cytotoxicity

Results:

Task 1a: siRNA – To demonstrate the specificity of this targeted approach, we first used PKC δ -specific lenti-viral based shRNA to efficiently knockdown PKC δ protein in a human prostate cancer cell line, DU145. We developed lentiviruses containing shRNA directed against PKC δ , or a scrambled shRNA. Viruses were titrated to determine moi for use. They were then used to infect prostate cancer cell lines. Even within 24 h, we observe very significant cytotoxicity, as assessed by LDH release (see **Fig. 1** for representative experiment). Parallel studies using these lentiviral vectors in other cell lines, including normal prostate cancer cells, are underway to validate the studies described below, which show marked sensitivity of a variety of prostate tumor cells to PKC δ inhibitors.

Task 1b. We will first describe the development of new specific PKC δ inhibitory molecules, and then show the results of the testing of these compounds on prostate cancer cell lines.

Pharmacophore Modeling and Development of new PKC δ Inhibitors: Highly isotype-specific PKC δ -inhibitory small molecules had not been identified by others to date. With our discovery and genetic validation that PKC δ is the specific target molecule for this Ras-targeted approach, we generated a pharmacophore model based on molecular interactions with “novel” class PKC isozymes. We established a initial pharmacophore model for PKC δ inhibitors, using mallotoxin/rottlerin [Lead Compound 1 (LC-1)] as a prototype structure for a moderately PKC δ -specific inhibitor (IC₅₀=5 μ M), and incorporated protein structural data for PKC ϵ , another member of the “novel” group of PKC enzymes, which is also inhibited by mallotoxin. LC-1 is a naturally-occurring product, with moderate aqueous solubility, and oral bioavailability.⁴ It inhibits purified PKC δ at an IC₅₀ of 3-5 μ M *in vitro*, and inhibits PKC δ in cultured cells with an IC₅₀ of 5 μ M *in vivo* (but at 0.5 μ M with exposure for >24 hrs, because of down-regulation of the PKC δ protein⁵). It is relatively selective for PKC δ over PKC α (PKC δ IC₅₀:PKC α IC₅₀ is approximately 30:1). Furthermore, as we have published, this compound not only directly inhibits purified PKC δ , but also, over longer periods of exposure, significantly down-regulates PKC δ protein specifically, while having no effect on the levels of other PKC isozymes.⁵ Thus, this compound inhibits PKC δ at two levels. We have demonstrated “Ras-specific” activity of this compound in a number of publications and assays (see above). Daily *i.p.* doses of up to 40 mg/kg (800 μ g/20 g) in mice do not produce any overt toxicity in our xenograft studies or others.⁴ Stability: Informal stability testing demonstrates >95% stability as a powder at room temp for >6 months. Toxicology: Pilot and published toxicity data indicate that the compound has a low toxicity profile (lowest lethal dose = 750 mg/kg, rat oral); 120 mg/kg (oral 6-day rat study) is the lowest toxic dose.^{6,7} This relative safety, combined with its *in vivo* efficacy, makes Lead Compound I attractive as a starting point for modification and drug development. We have demonstrated that better therapeutic candidates can be developed from it. The rationale for the development of new inhibitors was to improve the PKC δ -selectivity and potency. [Potential limitations on LC-1 itself as a therapeutic agent (despite its *in vivo* safety and activity) include its lack of high specificity for PKC δ ; its off-target effects, including inhibition of Cam Kinase III, MAPKAP-K2, and PRAK1 at IC₅₀s of <10 μ M; its non-PKC-mediated effects on mitochondrial uncoupling and modulation of death receptor pathways;^{8,9} and the lack of composition-of-matter IP around it, which would preclude eventual clinical development by big pharma.]

We designed and synthesized a 2nd generation set of analogs. In Analogs 1 and 2, the “head” group (A) was been made to resemble that of staurosporine, a potent general PKC inhibitor and other bisindoyl maleimide kinase inhibitors, with domains B and C conserved to preserve isozyme specificity. Ease of synthesis was a major factor in the design of this head group. Analogs 3 to 5 have “head groups” from other known kinase inhibitors: 1) Analog 3 from the crystal structure of an inhibitor bound to CDK2 (pdb code: 1FVT); 2) Analog 4 based on purine, found in a number of different potent kinase inhibitors; and 3) Analog 5 from a potent inhibitor of aurora kinase (pdb code 2F4J). The first 2nd generation chimeric molecule, KAM1, was indeed active, and more PKC δ -specific (see **Table 2**, below), and showed activity against cancer cells with activation of Ras or Ras signaling.¹⁰ Another 2nd generation compound we generated (CGX, with a very different composition but which fit the pharmacophore model) has demonstrated activity against multiple human cancer cell lines with activated K- or H-Ras alleles *in vitro* and *in vivo* in animal models. On the basis of SAR analysis of KAM1, we have this year generated 36 new 3rd generation compounds.

The PKC δ inhibitory activity and isozyme-specificity of the 36 3rd generation analogs was

assayed *in vitro*, using recombinant PKC isozymes, prior to comparative testing on prostate cancer cell lines.

Method: These assays utilize fluorogenic FRET detection (Z-lyte, R&D Systems) technology and peptide substrates, are robust and validated, and have been used to screen the 2nd and 3rd generation PKC δ inhibitors we have synthesized.

Results:

1. PKC δ Activity Assays of 3rd Generation Compounds

Recombinant PKC δ enzyme and FRET substrate. Compounds were tested at 5, 10 and 50 μ M. (Figs. 1-4)




Fig. 1: PKC δ activity, expressed as % inhibition. Compounds tested at the concentrations indicated (μ M).








Fig. 2: PKC δ activity, expressed as % inhibition. Compounds tested at the concentrations indicated (μ M).



Compounds with the highest inhibitory activity (106, 109, 111, 125) were too potent to allow assessment of IC₅₀s in the assays above, and the assays were repeated using lower concentrations of the inhibitors (**Figs. 5-6**).



2. PKC α Activity Assays of Selected 3rd Generation Compounds

Recombinant PKC α enzyme and FRET substrate were utilized. A standard curve is shown in **Fig. 7**. Selected compounds were tested at 5, 10 and 50 μ M. (**Figs. 8-9**)




Fig. 7: PKC α standard curve.




Fig. 8: PKC α activity, expressed as % inhibition. Compounds tested at the concentrations indicated (μ M).




Fig. 9: PKC α activity, expressed as % inhibition. Compounds tested at the concentrations indicated (μ M).

The data generated from replicates of the types of assays shown above were plotted for comparison (Fig. 10).




Figure 3. Inhibition effects of new PKC δ inhibitors on PKC isotopic kinase activity assays. (A). Kinase assay for their ability to inhibit PKC α activity. **(B).** Kinase assay for their ability to inhibit PKC δ activity. Activity curves showed that these inhibitors selectively inhibit PKC δ but PKC α .

Fig. 10: Plots of PKC α activity (A) and PKC δ activity (B), expressed as % control enzyme activity. Compounds tested at the concentrations indicated (μ M).

The information from the enzymatic activity/inhibitor assays above were compiled into a summary table (**Table 1**) for purposes of comparison.

Compound	PKC δ IC ₅₀	PKC α IC ₅₀	Cytotoxicity relative to Rottlerin			
			DU145	HRasG12V	NP-PCSC	P-PCSC
Rottlerin	4.4		xx	xxx	xxxx	xx
KAM-1	5.6					
B058	5.8		o	o	o	x
B071	3		o	o	o	o
B095	8		x	o	o	xx
B097	9.5		xx	o	o	o
B106	0.08	200	xxx	xxx	xxxx	
B108	3		o	o	o	o
B109	0.09	800	o	o	o	o
B111	2.5	100	x	o	o	
B112	6		xxx	xx	xx	xx
B117	4.5		o	o	o	o
B118	? 10		o	o	o	o
B121	4		o	o	o	o
B125	0.25	800	x	o	o	x
B128	6.5		xxx	o	o	xx
B129	6.5		x	o	o	x
B130	4		o	o	o	o
B131	10		o	o	o	o
B136	14		x	o	o	o
B137	3		o	o	o	o
B141	4.8		x	o	o	o
B142	3.5		o	o	o	o
B143	6		o	o	o	o
B146	5		o	o	o	o
B147	5.8		x	xx		x
B148	4		o	o	o	o
B149	0.31	>1000	x	xx	xx	o
B150	0.625	800	o	o	o	o
B151	< 0.05	>1000	o	o	o	o
B152	< 0.05	>1000	o	o	o	o
B153	3		o	o	o	o
B154	23		o	o	o	o
B155	3		o	o	o	o
B156	7.5		o	o	o	o
B157	5		o	o	o	o
B158	4.5		o	o	o	o
B159	7		xxxx	xx	xx	xx

Table 1: Summary PKC δ and PKC α inhibitory activity of 36 3rd generation compounds, expressed as IC₅₀. Summary of relative cytotoxicity on multiple prostate cancer cell lines, relative to rottlerin.

Interpretation: Certain of the 3rd generation compounds show substantially greater PKC δ inhibitory activity and specificity than LC-1 or 2nd generation compounds. For example, one such novel compound (“B106”) is much more potent than LC-1 (**Table 1**), producing substantial cytotoxicity against Ras-mutant tumor lines at concentrations ~40 times lower than LC-1. This compound is also active *in vivo*, in a Ras-mutant cell xenograft assay. Both LC-1 and B106 dramatically inhibited clonogenic capacity of Ras-mutant tumor cell lines after as little as 12 h exposure. A newer derivative of this particular compound (CGD63), not yet optimized with respect to drug-like properties, has a PKC δ IC₅₀ in the range of 0.05 μ M (compared to 3 μ M for LC-1), is 1000-fold more inhibitory against PKC δ than PKC α *in vitro*, and produces cytotoxic activity against Ras-mutant cells at nM concentrations. (Specificity for PKC δ over classical PKC isoforms, like PKC α , is important: inhibition of PKC α is generally toxic to all cells, normal and malignant, and would make our agent non-“tumor-targeted.”) We are therefore seeking to maximize PKC δ -isozyme-specificity for the inhibitors to retain the tumor-targeted cytotoxic properties. We will eventually test selected inhibitors against an entire panel of recombinant PKC isoforms, including the classical, novel and atypical classes.

Table 2 compares the 3 generations of PKC δ -inhibitory compounds tested to date.

Generation	PKC δ IC ₅₀	PKC α IC ₅₀	PKC δ /PKC α Selectivity	<i>in vitro</i> Ras-specific Cytotoxicity	<i>in vivo</i> Ras-specific Cytotoxicity
1	3 μ M	75 μ M	28-fold	3 μ M	Yes
2	2 μ M	157 μ M	56-fold	3-5 μ M ^b	Yes ^b
3 ^a	0.05 μ M	50 μ M	1000-fold	<0.5 μ M ^b	Not tested

^a not all 3rd generation compounds have been extensively tested. This is data from one of the most active 3rd gen compounds to date.
^b not yet optimized for drug-like properties, so *in vitro* activity represents a minimum of the potential activity.

Future Plans for Synthetic Strategy and Approach: A major goal of the next generation synthesis will be to *increase the drug-like properties of the drug candidate molecules*, as the 3rd generation molecules have not yet been optimized for drug-like properties (*e.g.*, improved water solubility; stability; ease of formulation; oral bioavailability and favorable toxicity profile). We will start by simply adding polar groups to the B106 scaffold, which is thus far the most promising analog. R1 and R2, which are hydroxyl groups in LC-1 and are hydrogen atoms in B106, will be sequentially substituted with OH groups which should improve water solubility. In addition, we plan to perform an isosteric replacement of the aromatic CH groups with basic nitrogen atoms which will be protonated at physiological pH providing for additional water solubility and perhaps improved potency. Based on the biological activity of these 4th generation of analogs, our SAR will be further guided by these outcomes. In addition, we plan to make the cap group from the staurosporine scaffold, more similar to the natural staurosporine structure with the ultimate goal of preparing the initial chimeric analog series. Space does not permit a detailed description of the synthetic plan but it can be said that these new 4th generation analogs do not pose a significant synthetic challenge and should be amenable to the basic synthetic chemistry platform that was developed to make KAM1.

3. Testing of 3rd Generation PKC δ Inhibitor Compounds in Prostate Cancer Cell lines

Materials and Methods:

- Cells were grown on 60mm tissue culture dishes, seeded to 1 x 10E5 cells per well:
- Cells were allowed to grow 24 hrs at 37oC and 5% CO₂.
- On treatment day, media was removed from each plate and replaced with either vehicle or test compound in growth media
 - ♦ DMSO (vehicle for compounds)
 - ♦ Compounds tested at various concentrations
- At 48 or 72 hrs, cells were harvested, and viable cell mass quantitated via MTT or MTS assay.

We have tested the entire panel of 36 3rd generation compounds against a prostate cancer cell line with an activating Ras mutation. The compounds were prepared in stock solutions as shown in **Table 2**. Results from representative cytotoxicity assays are shown below (**Figs. 11-15**)

BJE6	Molecular formula				FW	Weight (mg)	Mols (10 or 40mM stock)	Vol of diluent (ml) for Mols
	C	H	N	O				
-112	33	27	1	2	469.5730	8.5	0.01	1.810
-128	33	25	1	2	467.5571	9.8	0.01	2.096
-129	33	29	1	2	471.5889	6.4	0.01	1.357
-136	20	17	1	1	287.3551	7.6	0.01	2.645
-154	32	31	1	1	445.5947	4.0	0.01	0.898
-159	24	21	1	2	355.4291	7.2	0.01	2.026
-117	33	27	1	2	469.5730	30.4	0.04	1.618
-118	33	29	1	2	471.5889	45.5	0.04	2.412
-125	23	21	1	2	343.4184	24.9	0.04	1.813
-137	31	25	1	1	427.5363	17.6	0.04	1.029
-141	21	17	1	2	315.3652	50.3	0.04	3.987
-142	22	19	1	2	329.3918	75.3	0.04	5.715
-143	30	27	1	1	417.5415	36.6	0.04	2.191
-146	32	27	1	1	441.5629	33.8	0.04	1.914
-147	21	19	1	0	285.3823	12.6	0.04	1.104
-148	22	21	1	0	299.4089	30.7	0.04	2.563
-149	21	19	1	1	301.3817	14.2	0.04	1.178
-150	22	21	1	1	315.4083	29.3	0.04	2.322
-151	32	29	1	2	459.5782	34.7	0.04	1.888
-152	23	21	1	1	327.4190	44.4	0.04	3.390
-153	31	29	1	1	431.5681	28.3	0.04	1.639
-155	21	19	1	0	285.3823	52.4	0.04	4.590
-156	22	21	1	0	299.4089	55.4	0.04	4.626
-157	30	29	1	1	419.5574	25.9	0.04	1.543
-158	32	31	1	1	445.5947	40.8	0.04	2.289

Aliquot procedure:

1-Prep & label 15ml tubes

2-Dispense vol fo DMSO to labeled tubes

3-Take ~1ml out of tube and resuspend powder in vial

4-Transfer resuspended DMSO from vial to tube, rinse out vial with DMSO in tube.

Table 3




Fig. 11: Cell number (mass) at 48 or 72 h post exposure to the indicated compounds, expressed as OD490. Compounds tested at the concentrations indicated (μM).




Fig. 12: Cell number (mass) at 48 or 72 h post exposure to the indicated compounds, expressed as OD490. Compounds tested at the concentrations indicated (μM).




Fig. 13: Cell number (mass) at 48 or 72 h post exposure to the indicated compounds, expressed as OD490. Compounds tested at the concentrations indicated (μM).




Fig. 14: Cell number (mass) at 48 or 72 h post exposure to the indicated compounds, expressed as OD490. Compounds tested at the concentrations indicated (μM).




Fig. 15: Cell number (mass) at 48 or 72 h post exposure to the indicated compounds, expressed as OD490. Compounds tested at the concentrations indicated (μM).



Interpretation: Certain 3rd generation compounds (106, 147, 149, 112 and 159) show toxicity against this cell line comparable to LC-1 or greater than LC-1.

Task 1c) Determine the duration of PKC δ inhibition required to irreversibly initiate the apoptotic process.

Method/Assays:

1. Washout Studies: Exposure to inhibitors of PKC δ for different intervals of time, followed by washout, and assay of cell number over time. In this representative study, the DU145 cell line was used, and LC-1 (rottlerin) was used as the inhibitor (**Fig. 16A**).
2. Clonogenic Assays: Human prostate cancer stem cells in culture were exposed to a small-molecule inhibitor of PKC δ for 6, 18, 24, or 48 hrs, then the inhibitor was washed out and a clonogenic assay carried out. Colonies formed were enumerated. Treatment times indicate the duration of exposure to the inhibitor prior to replating (**Fig. 16B**).

Interpretation: Cytotoxic effects on prostate cancer cells are observed after exposure to PKC δ inhibitors for a period of 6 hrs. Longer periods of exposure produce progressively more toxicity. Replacing with fresh PKC δ inhibitors does not enhance the cytotoxic effect. These studies will be repeated using selected 3rd or 4th generation inhibitors.




TASK 2: Determine whether constitutive activation of *selected Ras effector pathways alone* is sufficient to make human prostate cancer cells susceptible to apoptosis after PKC δ inhibition: (utilizing prostate cancer cells with aberrant activation of the PI₃K pathway or aberrant activation of the Ras-MEK-ERK pathway).



Status: IN PROGRESS



Task 2a) PI₃K Pathway: utilizing the LNCaP line and prostate cancer lines with the commonly-occurring loss of PTEN [*e.g.*, DU145]¹¹


Progress:

We have tested the entire panel of 36 3rd generation compounds against a prostate cancer cell line with activation of PI₃K pathway. Examples of such studies are shown below (**Figs. 17-21**). Several of the most active compounds were then compared head-to-head (**Fig. 22**).









Interpretation: Certain 3rd generation compounds (106, 112, and 159) show toxicity against this cell line comparable to LC-1 or greater than LC-1). Interestingly, cytotoxicity did not always correlate with *in vitro* PKC δ inhibitory activity. (*e.g.*, the highly potent B109 had no activity in culture. We hypothesize that this is due to the highly-hydrophobic nature of some of these compound, inhibiting their entry into cells. Our next generation molecules will be optimized for drug-like properties to overcome this problem.

Task 2b) MEK-ERK Pathway: Human prostate cancer cell line CWR22Rv1 has constitutive, aberrant activation of the MEK-ERK signaling pathway, with wild type PTEN and PI₃K signaling

Progress: The analysis of effects of PKC δ inhibitors on CWR22Rv1 has not yet begun, as we are still determining the most potent and specific PKC δ -inhibitory compounds to be used for testing. We will only test the most potent compounds on the cells rather than extensive testing of the full current panel of 36 compounds, some of which are poor PKC δ inhibitors.

These lines will be tested for susceptibility to PKC δ knockdown by siRNA, or PKC δ inhibition by a small molecule inhibitor, with assay of cell numbers at 48 hrs by MTT assay.

TASK 3: Test the ability of PKC δ inhibitors to induce selective cytotoxicity in human prostate cancer stem cells.

Human prostate cancer stem cells (Oct 4, telomerase, SSEA 3/4 , and AP positive), and normal breast stem cells, are purchased from Celprogen (San Pedro, CA), cultured under conditions which maintain their undifferentiated state, and tested for their susceptibility to PKC δ knockdown by siRNA, or PKC δ inhibition by a small molecule inhibitor, with assay of cell numbers at 48 hrs by MTT assay

Status: IN PROGRESS

Progress:




Figure 2. Cytotoxic effects of PKC δ - knockdown by shRNA-lentivirus on human pancreatic and prostate cancer stem cells. Pancreatic CSC (A) and prostate CSC (B) were grown and infected with PKC δ -shRNA lentivirus or scrambled shRNA lentivirus (Vector) or vehicle controls (Vehicle). Cell cytotoxicity was evaluated by LDH-release assay and showed that LDH release/cytotoxicity were detected within 24 hours of exposure to the PKC δ shRNA, and this release increased as a function of time in both cancer stem cells.

We first demonstrated that prostate cancer stem cells (CSC) are susceptible to PKC δ suppression using siRNA (Fig. 23, panel B)




Fig. 24

We then tested LC-1 and 2nd generation PKC δ -inhibitory compounds on prostate cancer CSCs. Examples of such studies are shown below (Figs. 24A&B, 25)




Fig. 25




Fig. 26: Cell number (mass) at 48 or 72 h post exposure to the indicated compounds, expressed as OD490. Compounds tested at the concentrations indicated (μ M).










Fig. 27: Cell number (mass) at 48 or 72 h post exposure to the indicated compounds, expressed as OD490. Compounds tested at the concentrations indicated (μ M).



We have also now tested the entire panel of 36 3rd generation


PKC δ -inhibitory compounds against 2 prostate cancer stem cell cultures. Examples of such studies are shown below (Figs. 26-36)











Interpretation: Prostate cancer stem cell (CSC) lines are susceptible to PKC δ inhibition by siRNA or new small-molecule PKC δ inhibitors. Certain 3rd generation compounds (58, 106, 149, and 159) show toxicity against CSC lines comparable to LC-1 or greater than LC-1)

TASK 4: Test this Ras-targeted approach in an *in vivo* model of human prostate carcinoma.

Methods: Test this targeted approach in *in vivo* models of human prostate carcinoma. A xenograft model will be employed, utilizing an activating Ras-mutant human prostate carcinoma cell line (TSU-Pr-1) and a human prostate carcinoma cell line with aberrantly-activated PI₃K-signaling (PC3). In the last year, if time permits, a transgenic model of prostate cancer (the PB-Cre4 x PTEN(loxp/loxP) mouse), will be tested for sensitivity to this targeted therapeutic approach. Three cohorts of 15 immunodeficient (nu/nu) mice each, one vehicle control and two with different doses of the optimal PKC- δ inhibitor selected in TASK 1. Tumor growth will be serially quantitated.

Progress: This task has not yet been initiated, as we are waiting until the most potent small molecule inhibitors of PKC δ are identified prior to beginning these studies. We have established the MTD for B106, our lead compound at this time, and so are ready to initiate these studies.

KEY RESEARCH ACCOMPLISHMENTS: Bulleted list of key research accomplishments emanating from this research.

- Demonstrated the sensitivity human prostate cancers to PKC δ inhibition
- Showed activity of PKC δ inhibition against human prostate cancer stem cells
- Designed and synthesized 36 new compounds as PKC δ inhibitors
- Tested the activity of these 36 new compounds against PKC δ and PKC α
- Tested the activity of these 36 new compounds against human prostate cancer cells
- Tested the activity of these 36 new compounds against human prostate cancer *stem* cells
- Established MTD for our lead compound
- Determined the duration of exposure to PKC δ inhibitor drug necessary to achieve maximal cytotoxicity

REPORTABLE OUTCOMES: Provide a list of reportable outcomes that have resulted from this research to include:

None to date

CONCLUSION:

In our first year of work, we have made substantial progress. We have succeeded in demonstrating that multiple types of human prostate cancer cells are susceptible to PKC δ inhibition, using siRNA as a “specificity” test, and multiple structurally-distinct small molecule PKC δ inhibitors. These findings validate PKC δ as a target in prostate cancer, and provide proof-of-principle for the use of PKC δ inhibitors as potential therapeutics. Furthermore, we have shown the utility of PKC δ inhibition as a strategy for the elimination of prostate cancer stem cells. We have refined the initial PKC δ inhibitor lead compound now through 2 generations,

producing small molecules of increasing potency and PKC δ specificity. Our next generation will be optimized for “drug-like” properties, to facilitate moving into *in vivo* testing of tumor xenografts.

This *in vivo* testing in an animal will move these discoveries towards a medical product. Results of such studies will demonstrate the efficacy of this approach, provide informal toxicology, and informal PK.

REFERENCES:

1. Xia S, Chen Z, Forman LW, & Faller DV. PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1. *Cell Signal*. 21:502-8 (2009). PMID: 19146951
2. Iglehart JD & Silver DP. Synthetic lethality--a new direction in cancer-drug development. *N.Engl.J.Med*. 361:189-91 (2009).
3. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. *Nat.Rev.Cancer*. 5:689-98 (2005).
4. Zhang D, Anantharam V, Kanthasamy A, & Kanthasamy AG. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. *J Pharmacol.Exp.Ther*. 322:913-22 (2007).
5. Xia S, Forman LW, & Faller DV. Protein Kinase C{delta} is required for survival of cells expressing activated p21RAS. *J Biol.Chem*. 282:13199-210 (2007). PMID: 17350960
6. Varma DR, Sareen KN, Roy AK, & Gural ML. Oral contraceptive. Part IV. Hormonal and antihormonal effects of rottlerin. *Indian J Physiol Pharmacol*. 3:246-54 (1959).
7. Varma DR, Sareen KN, Roy AK, & Gural ML. Oral contraceptive. Part III. Further observations on the antifertility effect of rottlerin. *Indian J Physiol Pharmacol*. 3:168-72 (1959).
8. Maioli E, Torricelli C, & Valacchi G. Rottlerin and cancer: novel evidence and mechanisms. *ScientificWorldJournal*. 2012:350826. Epub@2012 Jan 4.:350826 (2012).
9. Song KS, Kim JS, Yun EJ, Kim YR et al. Rottlerin induces autophagy and apoptotic cell death through a PKC-delta-independent pathway in HT1080 human fibrosarcoma cells: the protective role of autophagy in apoptosis. *Autophagy*. 4:650-8 (2008).
10. Chen Z, Forman LW, Miller KA, English B et al. The proliferation and survival of human neuroendocrine tumors is dependent upon protein kinase C-delta. *Endocr.Relat Cancer* 18:759-71 (2011).

APPENDICES: None

SUPPORTING DATA: included above